Stock RANI RANI THERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 03:45:57 2024-06-10 pm EDT 		5-day change 1st Jan Change
4.1 USD -6.61% Intraday chart for Rani Therapeutics Holdings, Inc. -12.18% +23.80%
May. 16 UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating MT
May. 07 HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 322.3 145.8 85.92 115.5 - -
Enterprise Value (EV) 1 322.3 77.02 85.92 103.1 134.7 149.8
P/E ratio -38 x -4.61 x -2.5 x -4.37 x -5.55 x -7.67 x
Yield - - - - - -
Capitalization / Revenue 119 x - - - - 7.19 x
EV / Revenue 119 x - - - - 9.33 x
EV / EBITDA -6.31 x -1.22 x -1.32 x -1.67 x -2.03 x -3.89 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - 7.91 x - 37.4 x 63.3 x 5.37 x
Nbr of stocks (in thousands) 19,712 24,720 25,880 26,304 - -
Reference price 2 16.35 5.900 3.320 4.390 4.390 4.390
Announcement Date 3/31/22 3/22/23 3/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 2.717 - - - - 16.06
EBITDA 1 - -51.1 -62.9 -65.28 -61.87 -66.49 -38.47
EBIT 1 - -51.6 -63.45 -66.1 -55.65 -59.6 -51.66
Operating Margin - -1,899.12% - - - - -321.65%
Earnings before Tax (EBT) 1 - -53.05 -63.27 -67.88 -54.85 -59.41 -62.53
Net income 1 -16.7 -8.331 -30.59 -33.97 -29.32 -30.51 -31.2
Net margin - -306.62% - - - - -194.24%
EPS 2 -0.3600 -0.4300 -1.280 -1.330 -1.003 -0.7904 -0.5720
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 4/27/21 3/31/22 3/22/23 3/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - - - - - - - - - -
EBITDA 1 -13.25 -13.67 -15.72 -16.2 -17.31 -16.33 -18.1 -17.64 -13.21 -13.79 -16.16 -16.09 -14.96 - -
EBIT 1 -13.36 -13.78 -15.85 -16.34 -17.48 -16.52 -18.29 -17.86 -13.43 -14.03 -14.37 -14.42 -14.06 -7.25 -17.5
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -13.34 -13.76 -15.81 -16.32 -17.38 -16.83 -18.66 -18.33 -14.06 -14.78 -13.79 -14.12 -13.92 -7.995 -18.24
Net income 1 -5.189 -6.223 -7.624 -7.955 -8.786 -8.372 -9.303 -9.197 -7.098 -7.483 -7.162 -7.267 -7.362 -0.699 -10.95
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.2700 -0.2900 -0.3100 -0.3300 -0.3500 -0.3300 -0.3700 -0.3600 -0.2700 -0.2900 -0.2745 -0.2682 -0.2388 - -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 3/31/22 5/11/22 8/10/22 11/10/22 3/22/23 5/10/23 8/11/23 11/8/23 3/20/24 5/6/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 19.2 34.3
Net Cash position 1 - - 68.8 - 12.4 - -
Leverage (Debt/EBITDA) - - - - - -0.2887 x -0.8918 x
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - -72.6% - - -770% -4.22%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - - 0.7500 - 0.1200 0.0700 0.8200
Cash Flow per Share - -1.650 -1.950 - - - -
Capex - 0.51 1.62 - - - -
Capex / Sales - 18.62% - - - - -
Announcement Date 4/27/21 3/31/22 3/22/23 3/20/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.39 USD
Average target price
10.57 USD
Spread / Average Target
+140.81%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
RANI THERAPEUTICS HOLDINGS, INC. Stock Rani Therapeutics Holdings, Inc.
+26.81% 115M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.78% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.77% 108B
BIONTECH SE Stock BioNTech SE
-7.47% 24.21B
ARGENX SE Stock argenx SE
+2.07% 22.78B
GENMAB A/S Stock Genmab A/S
-10.79% 17.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.09% 16.37B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.68% 13.58B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.63% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RANI Stock
  4. Financials Rani Therapeutics Holdings, Inc.